Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Note Decision Allowing Pennsylvania Gynecomastia Verdict to Stand
"We are pleased that the Court saw fit to uphold this verdict, finding that the plaintiff presented sufficient evidence to show that negligence on the part of Janssen Pharmaceuticals led to his excessive breast development. In reducing the award, the Court determined that Maryland law applied to the case, as that is where the plaintiff resides. The final damages are the maximum amount allowable under that state's law," said Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently representing a number of Risperdal plaintiffs, and continues to provide free legal reviews to individuals who allegedly developed gynecomastia due to their use of the antipsychotic medication.
Johnson & Johnson and it Janssen Pharmaceuticals unit are currently facing at least 1,701 Risperdal lawsuits that have been centralized in a mass tort program currently underway in the Philadelphia Court of Common Pleas. All of the cases were filed on behalf of individuals who allegedly experienced gynecomastia and other complications related to their use of Risperdal. Plaintiffs accuse the drug makers of concealing the medication's serious side effects and of failing to warn doctors and patients of these risks. (In Re: Risperdal Litigation, Case Number 100300296).
So far, the proceeding has convened four trials involving Risperdal and gynecomastia. Plaintiffs were awarded financial damages in three of those cases, including the trial that concluded last November. On December 11, 2015, jurors in another case found that Johnson & Johnson and Janssen failed to provide doctors and patients with adequate warnings regarding its potential to cause gynecomastia, and awarded the plaintiff $500,000 in compensatory damages. (Case No. 130401984) In February 2015, another plaintiff was awarded $2.5 million, after the jury reached a similar conclusion regarding his excessive breast growth. (Case No. A-196444)
The following month, yet another jury found Risperdal's gynecomastia warnings to be inadequate. But the panel declined to award the plaintiff any damages after determining that there was not enough evidence to conclude that the drug had caused his condition. (Case No. 130301803)
Risperdal patients who allegedly developed gynecomastia connected with its use may be eligible to file their own lawsuit. To learn more about the ongoing Risperdal litigation, please contact Bernstein Liebhard LLP for a free case review by visiting the Firm's website, or by calling 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2016 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP